Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia
Less than 40% of patients with newly diagnosed adult immune thrombocytopenia will show spontaneous recovery within 12 months. Therefore, second-line treatments are frequently used to maintain a hemostatic platelet count or at best to cure the disease, with as few adverse effects as possible. Neverth...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Taylor & Francis Group
2020-04-01
|
| Seri Bilgileri: | Platelets |
| Konular: | |
| Online Erişim: | http://dx.doi.org/10.1080/09537104.2019.1636018 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|